-DOCSTART- O

U.S. I
judge O
orders O
Biogen I
, O
Berlex I
officials O
deposed O
. O

Leslie I
Gevirtz I

BOSTON I
1996-08-28 O

In O
order O
to O
help O
him O
decide O
whether O
he O
should O
hear O
the O
case O
, O
a O
U.S. I
District I
Court I
judge O
Wednesday O
ordered O
the O
legal O
counsels O
of O
Biogen I
Inc I
and O
Berlex I
Laboratories I
, O
a O
subsidiary O
of O
Schering I
AG I
, O
deposed O
. O

The O
tempest O
beyond O
the O
test O
tube O
involves O
allegations O
that O
the O
U.S. I
Food I
and I
Drug I
Administration I
violated O
the O
Orphan I
Drug I
law I
by O
allowing O
Biogen I
the O
right O
to O
sell O
its O
multiple O
sclerosis O
drug O
Avonex I
. O

Berlex I
also O
charges O
that O
Avonex I
is O
so O
similar O
to O
its O
MS O
drug O
, O
Betaseron I
, O
that O
it O
is O
a O
patent O
infringement O
. O

Both O
drugs O
are O
types O
of O
interferon O
. O

One O
analyst O
said O
sales O
of O
Avonex I
had O
already O
cut O
into O
Betaseron I
market O
share O
. O

BioVest I
Research I
, I
Inc I
's O
analyst O
Eddie I
Hedaya I
said O
, O
" O
Berlex I
sales O
are O
losing O
share O
like O
mad O
... O

my O
understanding O
of O
the O
marketplace O
is O
that O
they O
're O
below O
expectations O
. O
" O

He O
added O
Chiron I
Corp I
reported O
its O
sales O
of O
inventory O
to O
Berlex I
was O
down O
. O

Chiron I
makes O
Betaseron I
; O
Berlex I
markets O
it O
, O
he O
said O
. O

Biogen I
, O
in O
its O
Securities I
and I
Exchange I
Commission I
quarterly O
report O
for O
the O
period O
ending O
June O
30 O
, O
said O
it O
had O
earned O
$ O
6.1 O
million O
from O
Avonex I
sales O
during O
the O
drugs O
first O
six O
weeks O
on O
the O
market O
. O

When O
it O
approved O
Avonex I
in O
May O
, O
the O
FDA I
said O
both O
Biogen I
's O
product O
and O
Betaseron I
were O
developed O
under O
the O
incentives O
of O
the O
Ophran I
Drug I
Act I
which O
provides O
seven O
years O
of O
marketing O
exclusivity O
for O
products O
that O
treat O
rare O
diseases O
. O

Avonex I
" O
has O
been O
allowed O
to O
enter O
the O
market O
because O
it O
differs O
from O
interferon O
beta-1b O
( O
Betaseron I
) O
.. O

. O
" O

the O
FDA I
said O
. O

Now O
, O
U.S. I
District O
Judge O
Mark I
Wolf I
has O
ordered O
the O
chief O
counsel O
for O
Biogen I
, O
Michael I
Astrue I
, O
and O
Robert I
Chabora I
, O
his O
counterpart O
at O
Berlex I
be O
deposed O
about O
a O
May O
21 O
meeting O
the O
two O
men O
attended O
to O
help O
him O
determine O
whether O
the O
lawsuit O
filed O
by O
Biogen I
against O
Berlex I
should O
be O
heard O
in O
Massachusetts I
. O

Berlex I
filed O
a O
lawsuit O
against O
Biogen I
in O
U.S. I
District I
Court I
in O
Newark I
, O
N.J. I
in O
July O
, O
but O
Biogen I
had O
already O
filed O
a O
suit O
against O
Berlex I
in O
Massachusetts I
in O
May O
. O

Wolf I
ordered O
the O
depositions O
to O
determine O
if O
he O
or O
U.S. I
District O
Judge O
John I
Bissell I
of O
Newark I
should O
preside O
over O
the O
case O
. O

